{"title": "Current status of authorisations for combating COVID-19", "author": "\u00a9 Copyright Swissmedic", "url": "https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/stand-zl-bekaempfung-covid-19.html", "hostname": "swissmedic.ch", "description": null, "sitename": "swissmedic.ch", "date": "2020-11-25", "cleaned_text": "1 Review begins as soon as the formal check on the documents submitted is complete. The check lasts from a few hours up to a few days. 2 \"Under (rolling) review\" denotes that Swissmedic is examining the data submitted with regard to safety, efficacy and quality, is clarifying open issues with the companies and/or is demanding additional results 3Only the first authorisation in the context of COVID-19 is listed; for the sake of clarity, no indication extensions are shown 4Conversion to ordinary authorisation applied for, in respect of vaccine for which temporary authorisation had been issued. 5Temporary authorisation extended by Swissmedic (until official decision published, but not beyond 13.09.2023). 6Temporary authorisation extended by Swissmedic (until official decision published, but not beyond 15.01.2024). 7 Assessment as part of a simple update procedure Applications received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures. Authorisation procedures for vaccines against |Vaccination children aged from 6 months up to 5 years||02.09.2022|| | Authorisation of an Omicron-adapted vaccine from 18 years [Temporary authorisation](/swissmedic/en/home/news/coronavirus-covid-19/swissmedic-genehmigt-bivalente-covid-19-auffrischimpfung.html) Application for authorisation of a second bivalent COVID-19 vaccine [Authorisaton](/swissmedic/en/home/news/coronavirus-covid-19/smc-laesst-bivalente-covid-19-origial-omicron-ba4-5-auffrischimpfung-pfizer-zu.html) Examining |Vaccination from 12 years||15.06.2021||09.08.2021 | |Booster dose for persons at especially high risk, 3rd dose for persons with impaired immunity||10.09.2021||26.10.2021 | |Booster: Extension of the booster dose to everyone aged 18 years and over||10.09.2021||26.10.2021 | |Vaccination 6-11 years||17.11.2021||13.05.2022 | |Vaccination for children aged from 6 months up to 5 years||18.05.2022|| |[Temporary authorisation](/swissmedic/en/home/news/coronavirus-covid-19/bivalenten_covid-19_booster-impfstoff-genehmigt.html) Application for authorisation of a second bivalent COVID-19 vaccine [Authorisation](/swissmedic/en/home/news/coronavirus-covid-19/smc-laesst-bivalente-covid-19-origial-omicron-ba4-5-auffrischimpfung-moderna-zu.html) Examining vaccine | |Application for indication extension to 12 to 18-year-olds and booster dose||06.07.2022||02.09.2022 | |Nuvaxovid monovalent XBB.1.5 due to renunciation of distribution |Booster dose||22.12.2021||27.12.2021 ||01.06.2023 | Revocation of authorisation due to renunciation of distribution [Withdrawn](#accordion1694016906370) Authorisation procedures for indication Baricitinib) Lilly (Suisse) partial indication 02.02.2023 Authorisation of partial indication [Information for Etesevimab||Eli substance: Molnupiravir) |MSD Merck substance: Pharma S\u00e0rl||Treatment of Covid-19||14.12.2022||14.06.2023 | Withdrawn 1 Review begins as soon as the formal check on the documents submitted is complete. The check lasts from a few hours up to a few days. "}